Ann: PAT-DX1 engineering update, page-122

Hi kev,

I know nothing about the reproduction of antibodies, but as I see it, it is possible that the reproduction of whole antibodies (PAT-DX3) may be a more straight froward process than the production of PAT-DX1, which, in my mind would involve an additional step of cleaving the PAT-DX1 dimer from the whole PAT-DX3 antibody.

As Dr James Campbell said:
"This set-back to the timing of our PAT-DX1 program is matrial, but is offset by the significant advances being made with the PATDX3 manufacturing program and a range of business development activities.”
https://company-announcements.copyright link/asx/pab/c90da8f0-7c98-11ec-b43c-b28af01120e0.pdf

I'm guessing thet the production of PAT-DX3 is a preliminary step in the production of PAT-DX1, and the company has reported "significant advances being made with the PATDX3 manufacturing program".

On the other hand, the testing of PAT-DX1 is much further advanced than the testing of PAT-DX3, so I guess that the clinical trials for PAT-DX3 are also some way off.